The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer

Автор: Toropovskiy A.N., Nikitin A.G., Viktorov D.A., Solovev A.V., Khuzina R.M., Pavlova O.N.

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Клиническая медицина

Статья в выпуске: 5 (59), 2022 года.

Бесплатный доступ

Colorectal cancer is one of the most frequently diagnosed malignant tumors in men and women, which is a highly heterogeneous group of neoplasms consisting of subclasses with different molecular and clinical characteristics, and, as a consequence, patients with different types of tumors require different treatment protocols. Among the predictive factors of treatment response in patients with metastatic colorectal cancer, the most studied are the genes of the RAS family (KRAS, NRAS). Determination of RAS status is the first step in individual selection of drug therapy in patients with metastatic colorectal cancer. Patients with certain mutations in KRAS and NRAS genes are resistant to anti-EGFR therapy and have a lower median survival than WT (wild type) genotypes, indicating a negative prognosis in the presence of mutations.

Еще

Colorectal cancer, targeted therapy

Короткий адрес: https://sciup.org/143179585

IDR: 143179585   |   DOI: 10.20340/vmi-rvz.2022.5.CLIN.8

Список литературы The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer

  • Davydov M.I., Aksel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012. Vestnik RONC im. N.N. Blokhina = Bulletin of N.N. Blokhin Russian Cancer Research Center. 2014 (In Russ). [Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. ВестникРОНЦ им. Н.Н. Блохина РАМН. 2014].
  • Pancione M., Remo A., Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348. https://doi.org/10.1155/2012/509348
  • Bishehsari F., Mahdavinia M., Vacca M. et al. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014; 20(20): 6055-6072. https://doi.org/10.3748/wjg.v20.i20.6055
  • Kondo Y., Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):29-39. https://doi .org/10.1023/a:1025806911782
  • Cohen R., Pudlarz T., Delattre J.F. et al. Molecular targets for the treatment of metastatic colorectal cancer. Cancers (Basel). 2020;12(9):2350. https://doi.org/10.3390/cancers12092350
  • Issa J.P. Colon Cancer: It's CIN or CIMP. Clin Cancer Res. 2008;14(19):5939-5940. https://doi.org/10.1158/1078-0432.CCR-08-1596
  • Kwong L.N., Dove W.F. APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009;656:85-106. https://doi.org/10.1007/978-1-4419-1145-2_8
  • Brovkina O.I., Nikitin A.G. Mutations in KRAS and NRAS genes as biomarkers in colorectal cancer therapy and basic methods of their detection. Clinical Practice. 2021;12(1):66-71. [Бровкина О.И., Никитин А.Г. Мутации в генах KRAS и NRAS как биомаркеры в терапии колоректального рака и основные методы их детекции. Клиническая практика. 2021;12(1): 66-71 ]. https://doi.org/10.17816/clinpract63875
  • Linardou H., Briasoulis E., Dahabreh I.J. et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev. 2011;37(3):221-233. https://doi.org/10.1016/j.ctrv.2010.07.008
  • Pisareva E.E., Ljubchenko L.N., Kovalenko S.P., Shamanin V.A. Analysis of mutations in kras and braf genes in colorectal cancer in Russian patients. Siberian Journal of Oncology. 2016;15(2):36-41. (In Russ). [Писарева Е.Е., Любченко Л.Н., Коваленко С.П., Ша-манин В.А. Анализ мутаций в генах KRAS и BRAF при раке толстой и прямой кишки в российской популяции. Сибирский онкологический журнал. 2016;15(2):36-41]. https://doi.org/10.21294/1814-4861 -2016-15-2-36-41
  • Vaughn C.P., Zobell S.D., Furtado L.V. et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50(5):307-312. https://doi.org/10.1002/gcc.20854
  • Molina J.R., Adjei A.A. The Ras/Raf/MAPK Pathway. J Thorac Oncol Elsevier. 2006;1(1):7-9.
  • Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR., ERB B2., ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21(2):105-115.
  • Grothey A., Lenz H.J. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol. 2012;30(15):1735-1737. https://doi.org/10.1200/JC0.2011.40.4194
  • Shubin V.P., Pospekhova N.I., Tsukanov A.S., Rybakov E.G., Panina M.V., Sushkov O.I. et al. Frequency and spectrum KRAS mutations in different localization of colon cancer and anal cancer. Medicinskaâgenetika. 2014;13(5):3135. (in Russ). [Шубин В.П., Поспе-хова Н.И., Цуканов А.С., Рыбаков Е.Г., Панина М.В., Сушков О.И. и др. Частота и спектр мутаций в гене KRAS при раке толстой кишки разной локализации и раке анального канала. Медицинская генетика. 2014;13(5):3135].
  • Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008;28(6):742-754. https://doi.org/10.1592/phco.28.6.742
  • Lièvre A., Bachet J.B., Corre D.L. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-3995. https://doi.org/10.1158/0008-5472.CAN-06-0191
  • Diaz L.A., Williams R., Wu J. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-540. https://doi.org/10.1038/nature11219
  • Lampson B.L., Pershing N.L., Prinz J.A. et al. Rare codons regulate KRas oncogenesis. Curr Biol. 2013;23(1):70-75. https://doi.org/10.1016Zj.cub.2012.11.031
  • Porru M., Pompili L., Caruso C. et al. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. https://doi.org/10.1186/s13046-018-0719-1
  • Cox A.D., Fesik S.W., Kimmelman A.C. et al. Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discov. 2014;13(11):828-851. https://doi.org/10.1038/nrd4389
  • Liu M., Sjogren A.K., Karlsson C. et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci USA. 2010;107(14):6471-6476. https://doi.org/10.1073/pnas.0908396107
  • Tejpar S., Celik I., Schlichting M. et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30(29):3570-3577. https://doi.org/10.1200/JC0.2012.42.2592
  • Al-Mulla F., Keith W.N., Pickford I.R. et al. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer. 1999;24(4):306-14.
  • Munoz-Bellvis L., Fontanillo C., Gonzalez-Gonzalez M. et al. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density singlenucleotide polymorphism arrays. Mod Pathol . 2012;25(4):590-601.
  • Albanese I., Scibetta A.G., Migliavacca M. et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325(3):784-91.
  • Zauber P., Sabbath-Solitare M,. Marotta S.P., Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003;56(3):137-40.
  • Loupakis F., Pollina L., Stasi I. et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol . 2009;27(16):2622-9.
  • Scartozzi M., Bearzi I., Berardi R. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772-8.
  • Italiano A., Saint-Paul M.C., Caroli Bosc F.X. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol. 2005;16(9):1503-7.
  • Etienne-Grimaldi M.C., Formento J.L., Francoual M. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14(15):4830-5.
  • Tougeron D., Lecomte T., Pages J.C. et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2013;24(5):1267-73.
  • Baas J.M., Krens L.L., Guchelaar H.J. et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16(9):1239-49.
  • Mostert B., Jiang Y., Sieuwerts A.M. et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130-41.
  • Leder K., Foo J., Skaggs B. et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of preexisting resistance in chronic myeloid leukemia. PLoS One. 2011 ;6(11):e27682.
  • Oltedal S., Aasprong O.G., M0ller J.H. et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis. 2011;26(10):1271-7.
  • Ramaswamy S., Ross K.N., Lander E.S.,Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49-54.
  • McGranahan N., Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15-26 .
  • Misale S., Yaeger R., Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(404):532-6.
  • Fedyanin M.Yu., Elsnukaeva H.H.-M., Tjulandin S.A. Heterogeneity and clonal evolution of colorectal cancer. Advances in molecular oncology. 2017;4:24-34. https://doi.org/10.17650/2313-805X-2017-4-1-24-34
Еще
Статья научная
SciUp 2024 © 2024 ©